The Clinicopathological Characteristics and Prognoses of dMMR Gastric Adenocarcinoma Patients
Table 1
Clinical and pathological features of GC cancer patients ().
Clinical feature
Overall ()
Death ()
value
Recurrence ()
value
Sex
Male
105 (65%)
16 (64%)
19 (61%)
Female
57 (35%)
9 (26%)
12 (39%)
Age
≤55
42 (26%)
4 (16%)
8 (26%)
>55
120 (74%)
21 (84%)
23 (74%)
Family historya
Absent
147 (91%)
25 (100%)
29 (94%)
Present
15 (9%)
0 (0%)
2 (6%)
Number of tumor
Single
153 (94%)
22 (88%)
28 (90%)
Multiple
9 (6%)
3 (12%)
3 (10%)
Nerve invasion
Negative
117 (72%)
14 (56%)
16 (52%)
Positive
45 (28%)
11 (44%)
15 (48%)
Vascular tumor thrombus
Negative
101 (62%)
8 (32%)
11 (35%)
Positive
61 (38%)
17 (78%)
20 (65%)
Surgical approach
Laparotomy
143 (88%)
22 (88%)
28 (90%)
Laparoscopy
19 (12%)
3 (12%)
3 (10%)
Clinical stageb
Stage I
35 (22%)
2 (8%)
2 (6%)
Stage II
70 (43%)
3 (12%)
4 (13%)
Stage III
49 (30%)
16 (64%)
20 (65%)
Stage IV
8 (5%)
4 (16%)
5 (16%)
Number of LNc
≤6
103 (64%)
13 (52%)
15 (48%)
>6
59 (36%)
12 (48%)
16 (52%)
Tumor size
≤5 cm
103 (64%)
14 (56%)
18 (58%)
>5 cm
59 (36%)
11 (44%)
13 (42%)
Tumor location
Cardia
40 (25%)
12 (48%)
13 (42%)
Antrum
79 (49%)
8 (32%)
12 (39%)
Body
31 (19%)
5 (20%)
5 (16%)
Fundus
2 (1%)
0 (0%)
0 (0%)
Pylorus
1 (0%)
0 (0%)
0 (0%)
Angle
9 (6%)
0 (0%)
1 (3%)
Degree of differentiation
Poor
55 (34%)
10 (40%)
10 (32%)
Mediate
48 (30%)
7 (28%)
8 (26%)
Poor-med
55 (34%)
8 (32%)
12 (39%)
N/Ad
4 (2%)
0 (0%)
1 (3%)
Lauren classification
Intestinal
51 (31%)
6 (24%)
7 (23%)
Diffuse
34 (21%)
6 (24%)
8 (26%)
Mixed
55 (34%)
9 (36%)
12 (39%)
N/A
22 (14%)
4 (16%)
4 (13%)
HER2
3+
2 (1%)
1 (4%)
1 (3%)
0/1+/2+
156 (96%)
23 (92%)
29 (94%)
N/A
4 (2%)
1 (4%)
1 (3%)
dMMRe
MLH1
6 (4%)
2 (8%)
3 (10%)
PMS2
44 (27%)
10 (40%)
11 (35%)
MSH2
4 (2%)
0 (0%)
0 (0%)
MSH6
9 (6%)
2 (8%)
3 (10%)
MLH1+PMS2
93 (57%)
10 (40%)
13 (42%)
MSH2+MSH6
5 (3%)
1 (4%)
1 (3%)
PMS2+MSH2+MSH6
1 (1%)
0 (0%)
0 (0%)
Treatment pattern
Surgery alone
84 (52%)
14 (56%)
16 (52%)
Neoadjuvant chemotherapy
14 (9%)
4 (16%)
6 (19%)
Postoperative adjuvant chemotherapy
61 (38%)
7 (28%)
9 (29%)
Postoperative immunotherapy
2 (1%)
0 (0%)
0 (0%)
Postoperative chemoradiotherapy
1 (0%)
0 (0%)
0 (0%)
aHistory of tumorigenic first- and second-degree relatives. bTNM staging classified according to the Union for International Cancer Control (UICC) TNM classification, 8th edition. For patients with multiple lesions, T staging was performed for the lesion with the highest T stage. cThe number of regional lymph nodes with metastases identified during surgery. dN/A indicates either that testing was not done or that the results could not be evaluated. edMMR status based on the IHC staining of MMR proteins and the loss of any MMR proteins.
